NeuroTimone Facility (PFNT)

The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.


  1. Marseille - Cassis 2019
  2. Anne-Marie François Bellan
    Listening to our molecular clocks

    During the NeuroStories event, held on Monday October 7 at the Faculty of Medicine, Anne-Marie François Bellan gave a remarkable stand up on how our body vibrates to the rhythm of internal chronometers called circadian clocks. She also explained how the molecular clock uses small corpuscles and cell space to make our genes rhythm.

    Click on the news to  see the video of her brilliant speech.





  3. Prof. D. Figarella-Branger, who belongs to the cIMPACT-NOW Working Committee, attended to the last meeting of the consortium in Utrecht (16-17 september).

    The cIMPACT-NOW Working Committee is the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. cIMPACT-NOW  was created in late 2016 —following publication of the 2016 Updated 4th Edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System— to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications.

  4. Three members of INP presented their work on Glioma during the 14th EANO annual meeting held in Lyon (19 - 22 September, 2019)

    During the 14th EANO annual meeting 3 members of INP team #8 presented their work on Glioma in a plenary conference «CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas» Dominique Figarella Branger, a short talk «Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls» Emeline Tabouret and two posters «P11.06: Non epigenetic effect of vorinostat in glioblastoma cells» and «EB1-dependant long survival of glioblastoma cancer stem-like cells tumor

  5. Nadia Merad Coliac and Maxime Bonnet joined the NOSE team

    Nadia Merad Coliac, plastic designer, joined the NOSE (Nasal Olfactory Stemness and Epigenesis) team, as an Associate researcher. At the crossroads of several disciplines, she develops an experimental work of art and science, in the field of bioluminescence. She is considering a therapeutic application in patients with autism spectrum disorders (ASD). Recently, Nadia published Lumière vivante - Théorie et pratique de la bioluminescence (Living light - theory and use of bioluminescence) - L’Harmattan eds.

  6. New publication from the GlioME Team (INP team 8) in Cancers pointing at A2B5 as an attractive therapeutic target for glioblastomas.
  7. F. Devred and E. Tabouret presented their research work at the annual Canceropole PACA meeting
  8. INP team 8 and 9 and PINT members presented their work at the 4th French Microtubule Network

    INP team 8 and 9 and PINT members being part of the French Microtubule Network, several members presented their work at the 4th French Microtubule Network gathering in Rennes on the 1srt and 2nd july 2019, in the  "Microtubules and their regulators : new therapeutic targets" session and the "Microtubules, assembly and regulation" session. Pascale Barbier presented her work "", Raphael Berges his work "Proscillaridin A exerts anti-tumor effects through"GSK3 activation and alteration of microtubule dynamics in glioblastoma" and François Devred a new method of "Functional screening of therapeutic agents and targets using nanoDSF "


INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD


The GlioME team published a new article in Oncotarget journal: EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis.

Our study shows that a treatment with the microtubule-destabilizing agent BAL101553 counteracts tumor angiogenesis by acting on glioblastoma stem-like cells, in an EB1-dependent manner. This work provides new insights into the therapeutic targeting of cancer stem-like cells.


Aurélie Tchoghandjian, jeune chercheur dans l'équipe GlioME a brillament obtenu son Habilitation à Diriger les Recherches (HDR)

Aurélie Tchoghandjian a soutenu son Habilitation à Diriger les Recherches (HDR) devant un jury d'experts composé de cliniciens : Pr. Nicolas André, Pr. François Ducray, Pr. Dominique Figarella-Branger; et de chercheurs : Dr. Emmanuelle Huillard et Dr. Monique Dontenwill.


New publication from Sylvie Carmona (Neuro-inflammation and Multiple Sclerosis team - INP team 5)

As part of her PhD, Sylvie Carmona investigated the beneficial effects of NV669, an aminosterol derived from squalamine on human pancreatic and hepatic cancer models. In vitro results exposed in this paper showed that NV669 inhibited the proliferation of cancer cells, induced cell cycle arrest and subsequent apoptosis. Moreover, NV669 inhibited PTP1B activity and impacted adhesion molecules expression. This suggests that NV669 by inhibiting PTP1B would affect cell contacts and would induce apoptosis.


Deux nouveaux arrivants dans l'équipe GlioME

L'équipe 8 (GlioME) a le plaisir d'accueillir deux étudiants en Master 2, Anaïs Arathni étudiante en Master Biologie Santé et Emmanuel Snacel-Fazy étudiant en Master Neurosciences. Anaïs travaillera avec Aurélie Tchoghandjian sur la caractérisation des cellules immunitaires recrutées sur le site tumoral suite au traitement par mimétiques de Smac. Emmanuel travaillera avec Chiara Bastiancich sur le microenvironnement de la résection tumorale du glioblastome.


A commentary from Christophe Leterrier in the Journal of Cell Biology

Christophe Leterrier, leader of the NeuroCyto ATIP team, wrote a Spotlight in the Journal of Cell Biology highlighting a nice recent paper from the group of Pei-Lin Cheng in Taiwan. In this article, Lee et al. showed how degradation of the chloride transporter NKCC1 by proteasomes anchored at the AIS have a key role in lowering the intracellular chloride concentration, leading to the perinatal reversal of GABA effect from excitatory to inhibitory.